Arrowhead Sci-Tech Conferences and Events today announced the 4th Annual Psychedelic Therapeutics and Drug Development Conference, the flagship event for research and therapeutics development in the psychedelics space. The event will be held May 23-24, 2024, at the iconic Revere Hotel Boston Common in Boston, MA. The two-day event is expected to attract the world’s leading researchers and thought leaders in academia, industry, the non-profit sector, and government that aim to bridge gaps in the research and development (“R&D”) sphere related to therapeutic psychedelics. The conference will focus on the R&D of psychedelics for various health conditions with considerable unmet needs, including inflammatory/autoimmune disorders, brain injury, pain, PTSD, anxiety, ADHD, headaches, depression, and opioid use disorder. It is curated to optimize business efficacy and impart invaluable practical guidance for collaborative partnerships among disparate disciplines with common objectives. Its elite roster of speakers will share insights and wide-ranging perspectives on various core themes, including Clinical Trial Design, Intellectual Property, Regulatory Guidance, and more. In addition, nearly 40 industry thought leaders will engage and interact with attendees in in-depth presentations and lively panel discussions. Attendees will also have the unique opportunity to delve into developments at the cutting edge of psychedelic therapeutics while select researchers present their studies during highly innovative scientific poster sessions. The agenda also includes abundant networking opportunities.
To view the full press release, visit https://ibn.fm/HmIsT
About Arrowhead Sci-Tech Conferences & Events
Arrowhead Sci-Tech Conferences & Events is more than a life sciences event company. Its focus is on bringing the developments and discoveries in life sciences research together to help further progress. The company utilizes its years of experience to provide attendees with thoughtfully curated speakers for life sciences conferences that highlight new research, industry trends, case studies, emerging discoveries and the future focus of the biotech and pharmaceutical industries. Its conferences cover: clinical development and cutting-edge research, regulatory issues and market dynamics, therapeutics, drug discovery and positioning, and emerging technologies for both clinicians and pharmaceutical professionals. To book tickets for the 4th Annual Psychedelic Therapeutics and Drug Development Conference, visit https://psychedelics-conference.com/pricing. For more information on the event, visit https://psychedelics-conference.com/.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN
